Table 2 Main methodological characteristics of schizophrenia drug trials published in Italy from 1948 to 2009 (n = 81 studies)
From: Forty-five years of schizophrenia trials in Italy: a survey
| Â | n | % (95% CI) |
|---|---|---|
Sample size | Â | Â |
Min-20 | 22 | 27.1 (17.8-38.1) |
21-40 | 32 | 39.5 (28.8-50.9) |
40-max | 27 | 33.3 (23.2-44.6) |
Length of follow-up (weeks) | Â | Â |
Unclear | 10 | 12.3 (6.08-21.5) |
2-4 | 30 | 24.6 (15.7-35.5) |
5-12 | 21 | 25.9 (16.8-36.8) |
13+ | 20 | 24.6 (15.7-35.5) |
Randomization | Â | Â |
Randomized, no details | 51 | 62.9 (51.5-73.4) |
Randomized with details | 7 | 8.6 (3.54-16.9) |
Unclear | 23 | 28.4 (18.9-39.5) |
Blinding | Â | Â |
Single blind | 6 | 7.4 (2.76-15.4) |
Double blind | 47 | 58.0 (46.5-68.9) |
Unclear | 28 | 34.5 (24.3-45.9) |
Outcome measures (n) | Â | Â |
1-5 | 33 | 40.7 (29.9-52.2) |
6-15 | 35 | 43.2 (32.2-54.6) |
16-60 | 13 | 16.0 (8.83-25.8) |
Patient flow diagram | Â | Â |
Yes | 2 | 2.4 (0.30-8.63) |
No | 79 | 97.6 (91.3-99.6) |